An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
About the study
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
- Presence of measurable tumor
- Able to swallow medication
EXCLUSION CRITERIA
Exclusion Criteria:
- Major surgery within 4 weeks before randomization
- Last dose of prior chemotherapy received less than 4 weeks prior to randomization
- Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
- Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
- Significant cardiac events
- Previous ZD6474 treatment
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Thyroid Cancer
Age (in years)
18+
Phase
Phase 3
Participants needed
437
Est. Completion Date
Jun 28, 2024
Treatment type
Interventional
Sponsor
Sanofi
ClinicalTrials.gov identifier
NCT00410761
Study number
D4200C00058
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?